BioTime, Inc. (BTX) Analysts See $-0.06 EPS

February 23, 2018 - By Adrian Mccoy

 BioTime, Inc. (BTX) Analysts See $ 0.06 EPS
Investors sentiment decreased to 1.96 in 2017 Q3. Its down 0.17, from 2.13 in 2017Q2. It is negative, as 9 investors sold BioTime, Inc. shares while 15 reduced holdings. 9 funds opened positions while 38 raised stakes. 49.13 million shares or 2.79% more from 47.80 million shares in 2017Q2 were reported.
Ontario – Canada-based Scotia Capital has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Iowa Bankshares has 10,000 shares for 0.01% of their portfolio. Jacobs Levy Equity Mngmt Inc holds 141,752 shares. Dimensional Fund Advsrs Limited Partnership reported 156,721 shares or 0% of all its holdings. Indexiq Advsr Limited Liability Corp invested in 0.03% or 251,227 shares. Swiss Bancorp holds 0% or 110,586 shares. Moreover, Virtu Fincl Ltd Liability Corporation has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 16,223 shares. Quantitative Systematic Strategies Lc has 0.01% invested in BioTime, Inc. (NYSEAMERICAN:BTX). Douglass Winthrop Advsrs Llc has 10,000 shares for 0% of their portfolio. American Inc holds 50,747 shares or 0% of its portfolio. The Switzerland-based Credit Suisse Ag has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Voya Invest Mngmt Ltd Liability Com, a Georgia-based fund reported 32,496 shares. 37,000 were accumulated by Carl Domino. Bancorp Of Ny Mellon Corp holds 461,000 shares or 0% of its portfolio. Williams Jones Ltd Co invested in 80,740 shares or 0.01% of the stock.

Since October 13, 2017, it had 1 insider buy, and 0 insider sales for $7.00 million activity.

Analysts expect BioTime, Inc. (NYSEAMERICAN:BTX) to report $-0.06 EPS on March, 15.After having $-0.05 EPS previously, BioTime, Inc.’s analysts see 20.00 % EPS growth. The stock decreased 0.38% or $0.01 during the last trading session, reaching $2.63. About 240,894 shares traded. BioTime, Inc. (NYSEAMERICAN:BTX) has risen 22.71% since February 23, 2017 and is uptrending. It has outperformed by 6.01% the S&P500.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $333.66 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 6.12 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More news for BioTime, Inc. (NYSEAMERICAN:BTX) were recently published by: Businesswire.com, which released: “and Vision Restoration Programs to Be Presented at ARVO 2018” on February 15, 2018. Businesswire.com‘s article titled: “BioTime Appoints Cavan Redmond to Its Board of Directors” and published on February 22, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.